MEDIGARD RIGHTS ISSUE TO RAISE $4.8M

Written on the 9 August 2010

MEDIGARD RIGHTS ISSUE TO RAISE $4.8M

LISTED medical technology company Medigard (MGZ) has launched a rights issue for shareholders as it undertakes a $4.8 million capital raising to manufacture its blood collection device in the US.

Medigard will offer existing shareholders 74,406.091 new shares at 6.5c with an attached option for 9.5c if exercised before June 30, 2011.

The company needs to raise at least $1.57 million to get the US manufacturing process underway.

CEO Peter Emery, says the capital will inject additional funds into R&D, IP and working capital.

“That’s what we need in the very minimum just to get the tooling completed on the blood collection device,” he says.

“The $4.8 million is deliberate to give our own investors an opportunity under the rights issue. We believe it’s a pretty attractive offer.”

A cornerstone US investor is also being sought to propel the company to the next stage of production.

Emery expects to see revenues within 18 months with up to US$40m annual revenue forecast over a five year period following a recent deal with distributor Outcome Solutions and an undisclosed manufacturer.

The initial agreement is to supply a minimum 10 per cent of 700 million BCDs consumed by the US market per year. Four other Medigard products will also be put into production under the agreement.

The company chose the US over Asian export markets to ensure the quality of the products is maintained.

“Through selecting the right manufacturer, we will be able to deliver a price competitive product that is also of the highest quality, which will be of key importance to our success in the US market,” says Emery.

“These two key agreements we have been working towards for some time and are the culmination of months of negotiation, personal visits and the necessity of building key relationships.

“Both of our partners are commercially savvy and experienced operators and we look forward to working with them not only on the BCD, but also in development and production of our pipeline of products starting next with our 3mL syringe.”

MGZ shares rose 33.33 per cent today to $0.12.


Latest News

NEW CLASS OF EDUCATION NURTURES ENTREPRENEURS OF TOMORROW

THE rise in youth unemployment has affirmed the importance of entrepreneurship education, and south-east Queenslan...

DUET GROUP SUBJECT OF $7.3 BILLION TAKEOVER OFFER

HONG Kong's Cheung Kong Infrastructure has launched a $7.3 billion cash bid for one of Australia's largest en...

G8 SHARES BUOYED BY FORECAST PROFIT RECOVERY

CHILDCARE centre operator G8 Education (ASX:GEM) has revealed it is on track to post a pre-tax profit of up to $16...

BELLAMY'S FINDS EXPORTING BABY FORMULA INTO CHINA IS NO CHILD'S PLAY

BELLAMY'S (ASX: BAL) shares have suffered a 40 per cent drop in value today after the company hit a regulatory...

Related News

JB HI-FI IS THE GOOD GUY IN $870 MILLION ACQUISITION

ELECTRONICS giant JB Hi-Fi has formally completed its $870 million acquisition of home appliance chain The Good Gu...

ACCC ACTS AGAINST MERITON'S RIGGED REVIEWS

MERITON Property Services is under fire from Australia's main consumer watchdog, after it allegedly engaged in mi...

ACCC FIRES WARNING SHOT TO IVF PROVIDERS

IVF clinics have been put on notice by consumer watchdog, the Australian Competition and Consumer Commission (ACCC...

BIG W CEO QUITS AFTER 11 MONTHS

SALLY MacDonald has resigned as chief executive of BIG W ending her tenure at the helm of the struggling discount ...

Contact us

Email News Update Sign Up Contact Details

Subscribe to our mailing list

* indicates required
Email Format

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter